Diagnostic test based on urinary tumor markers hold promise for earlier or prompt detection of bladder cancer in patients ...
Pfizer (NYSE:PFE) and Astellas Pharma reported positive pivotal Phase 3 results for PADCEV plus Keytruda in muscle invasive bladder cancer. The EV-304 (KEYNOTE-B15) trial showed a substantial ...
The founder said that 50% of enrolled patients in the Phase 3 bladder cancer study reached an evaluable efficacy endpoint, ...
Bladder cancer can cause pain when it spreads to different areas of the body. From NSAIDs to nerve blocks, here are the ...
Khaberni - A number of researchers from the College of Medicine at Stanford University, Columbia University, and Beaumont ...
Pfizer Inc. (NYSE:PFE) is among the 13 Most Undervalued S&P 500 Stocks to Invest In. On February 27, 2026, Pfizer Inc.
A growing body of research seeks to validate ctDNA as a means of guiding MIBC treatment, particularly immunotherapy.